Alkermes PLC 8-K filings

Alkermes announced a solid third quarter in 2024, with a notable 18% year-over-year increase in net sales of proprietary products and GAAP net income from continuing operations of $92.8 million.

Alkermes is progressing its orexin portfolio, highlighted by ALKS 2680, a differentiated orexin 2 receptor agonist, currently in Phase 2 trials for narcolepsy and idiopathic hypersomnia, while also exploring broader applications in neurology and psychiatry.

Alkermes announced a profitable second quarter of 2024, with a 16% year-over-year increase in net sales of proprietary products and GAAP net income from continuing operations of $94.7 million.

Alkermes shareholders approved amendments to the 2018 Stock Option and Incentive Plan, including an increase in authorized shares and changes to treatment upon a sale event, and elected directors at the annual general meeting.

Alkermes announced a profitable first quarter of 2024 with $350.4 million in revenue, marking its first full quarter as a pure-play neuroscience company.

Alkermes reports positive topline results from a Phase 1b study of ALKS 2680, showing improved wakefulness in patients with narcolepsy type 2 and idiopathic hypersomnia.

Alkermes plc has appointed Nancy S. Lurker, a seasoned healthcare executive, to its Board of Directors, increasing the board size to eleven members.

Alkermes reported a profitable 2023 with significant revenue growth and provided positive financial expectations for 2024, driven by its focus on neuroscience.

Alkermes has temporarily appointed Blair C. Jackson as interim principal financial officer and Samuel J. Parisi as interim principal accounting officer while Iain M. Brown is on medical leave.